Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
20 hedge funds and large institutions have $235K invested in Evofem Biosciences, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 6 closing their positions.
17% less funds holding
Funds holding: 24 → 20 (-4)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
86% less capital invested
Capital invested by funds: $1.74M → $235K (-$1.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
+$22K |
| 2 |
Goldman Sachs
New York
|
+$21.7K |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
+$11.8K |
| 4 |
UBS AM
Chicago,
Illinois
|
+$4.1K |
| 5 |
Citigroup
New York
|
+$77 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$105K |
| 2 |
Two Sigma Investments
New York
|
-$86K |
| 3 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$49K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$23K |
| 5 |
Two Sigma Advisers
New York
|
-$10.8K |
EVFM Hedge Fund Activity: Q1 2016 in Review
20 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q1 2016, worth a combined $235K — down 86% from $1.74M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of EVFM and 3 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 2 added.
The largest buyer was A.R.T. Advisors, adding an estimated $22K. The largest seller was Vanguard Group, cutting an estimated $105K.
- 20 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q1 2016, down from 24 in Q4 2015.
- Funds reported $235K of Evofem Biosciences, Inc. Common Stock stock for Q1 2016, down 86% quarter-over-quarter.
- 3 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q1 2016 and 6 closed out, a net change of -3 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q1 2016 was A.R.T. Advisors, an estimated $22K added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q1 2016 was Vanguard Group, an estimated $105K sold.
Based on aggregated 13F filings for Q1 2016.